Process and analytical insights for GMP manufacturing of mRNA lipid nanoparticles
Sep
28
2022
On demand

Process and analytical insights for GMP manufacturing of mRNA lipid nanoparticles

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
Process and analytical insights for GMP manufacturing of mRNA lipid nanoparticles

The successful development and rapid deployment of the messenger RNA (mRNA) vaccines against SARS-CoV-2 virus has catalyzed the industry to look more closely at the technology beyond its potential use for novel vaccines to enable breakthrough treatments for cancer, rare diseases, and more. However, the absence of standardized protocols means manufacturers must develop and optimize their process, leading to a considerable number of variables and decisions throughout the production workflow.

This webinar will discuss key insights into the potential of the mRNA and lipid nanoparticle (LNP) technologies that underpin the COVID-19 vaccines, barriers to successful industrialized manufacture of mRNA–LNPs, and approaches to optimizing process development and manufacturing. The panel will address:

  • The 5 steps of manufacturing mRNA-LNP drug products, including DNA template manufacturing, mRNA drug substance synthesis and purification, mRNA–LNP formulation and purification, fill/finish operations, and analytical testing
  • Process and analytical considerations for GMP manufacturing of mRNA-LNPs
  • Challenges and opportunities for mRNA-LNP therapeutic development


Emmanuelle Cameau
Emmanuelle Cameau
Gene Therapy Strategic Technology Partnership Leader EMEA Pall Corporation

Emmanuelle Cameau is a Senior Bioreactor Applications Scientist within the Scientific Laboratory Services (SLS) at Pall Biotech. Highly skilled in the field of cell culture applications and with 10+ years of experience, Emmanuelle previously held positions as a Bioprocess Specialist at Pall, and a Biotech Process Sciences Upstream Process Development Engineer at Merck Serono. She received her Biotechnology Engineer diploma from the former Ecole Supérieure d’Ingénieurs de Luminy (now Polytech Marseille).

Peiqing Zhang
Peiqing Zhang
Gene Therapy Strategic Technology Partnership Leader APAC, Pall Corporation
Shell Ip
Shell Ip
Client Learning & Scientific Content Manager, Precision NanoSystems
Linda Mathiasson
Linda Mathiasson
Strategic Customer Lead, Nucleic Acid Therapeutics, Cytiva
Katarina Stenklo
Katarina Stenklo
Enterprise Commercial Activation & End-to-end Solutions Leader, Cytiva

SPEAKERS

Emmanuelle Cameau
Emmanuelle Cameau
Gene Therapy Strategic Technology Partnership Leader EMEA Pall Corporation
Peiqing Zhang
Peiqing Zhang
Gene Therapy Strategic Technology Partnership Leader APAC, Pall Corporation
Shell Ip
Shell Ip
Client Learning & Scientific Content Manager, Precision NanoSystems
Linda Mathiasson
Linda Mathiasson
Strategic Customer Lead, Nucleic Acid Therapeutics, Cytiva
Katarina Stenklo
Katarina Stenklo
Enterprise Commercial Activation & End-to-end Solutions Leader, Cytiva

You might also like